Platelet aggregation contributes to the onset of acute coronary syndrome, and current guidelines recommend dual antiplatelet therapy, including a P2Y12 antagonist and aspirin, for at least 12 months after the cardiovascular event [4]. This evidence concerns the gene P2RY12 and acute coronary syndrome.